On May 28, Smoore International fell 3.46% in regular trading, trading at HK$9.2 per share, with trading volume of HK$25.42 million.

On the news front, the U.S. FDA previously approved non-tobacco flavored e-cigarettes through PMTA review for the first time, pushing the stock up over 20% within the month. However, since May 14 the stock has been in continuous pullback. A brief stabilization and rebound on May 22 failed to hold, and the stock has resumed its downward drift. The current decline reflects ongoing profit-taking pressure, with notably shrinking trading volumes indicating strong wait-and-see sentiment among market participants.

Institutional analysts remain constructive on Smoore International's medium-to-long-term outlook, noting that the company's underage-user identification technology was a key consideration in the FDA approval process. Core client products and proprietary brands are expected to accelerate their regulatory approvals, positioning the company to directly benefit from a recovery in the compliant e-cigarette market.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)